Cardiovascular Risk Scoring of Hospitalized Chronic Kidney Disease Patients by Framingham Risk Score

M K Alam1, A Hasan, M Paul

  • 1Dr Mohammad Khurshadul Alam, Medical Officer, National Institute of Cardiovascular Disease (NICVD), Dhaka, Bangladesh;

PubMed

Insights

Chronic kidney disease (CKD) patients face high cardiovascular disease (CVD) risks. This study found age, male gender, smoking, and high cholesterol are key CVD risk factors in CKD patients.

Area of Science:

  • Nephrology
  • Cardiology
  • Public Health

Background:

  • Patients with chronic kidney disease (CKD) exhibit a significantly higher prevalence of cardiovascular diseases (CVD).
  • Assessing cardiovascular risk is crucial for managing CKD patients and preventing adverse events.

Purpose of the Study:

  • To estimate the risk of cardiovascular events in chronic kidney disease patients using Framingham's Risk Score.
  • To identify predominant cardiovascular risk factors among CKD patients.

Main Methods:

  • A cross-sectional descriptive study involving 100 CKD patients admitted to Chittagong Medical College Hospital.
  • Cardiovascular risk was assessed using Framingham's criteria, with estimated glomerular filtration rate (eGFR) calculated via the MDRD formula.
  • Data were analyzed using SPSS-18.0.

Main Results:

  • Most patients were under 60 years old, with males (56.0%) more prevalent than females (44.0%).
  • Males were predominantly in the high-risk cardiovascular group. Higher risk was associated with elevated total cholesterol (212.17mg/dl) and low HDL (38.58mg/dl).
  • Significant positive correlations were observed between age and serum total cholesterol with cardiovascular risk scoring.

Conclusions:

  • Age, male gender, smoking, and high total cholesterol are significant cardiovascular risk factors in CKD patients.
  • The findings highlight the need for targeted cardiovascular risk management strategies in CKD populations.

Related Concept Videos

Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
95
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
94
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
388
Dialysis01:27

Dialysis

Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
320
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
433
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
94